Pfizer’s 2025 guidance positions company for EPS expansion, says BMO

BMO Capital reiterated an Outperform rating and $36 price target on Pfizer (PFE), saying that 2025 guidance succeeds in meeting the majority of the firm’s expectations outlined in its preview, positioning the company for earnings per share expansion. The company’s guide only just missed the firm’s midpoint sales expectation, though midpoint EPS expectations of $2.90 in 2025 show roughly 2% growth year-over-year, giving investors confidence that the company has turned over a new leaf financially, the analyst tells investors in a research note. The firm continues to believe the revenue guidance is conservative, especially for ex-COVID products, leaving room for future beats and raises to sustain shares throughout the year.